Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors
Excerpt from the Press Release:
BOSTON–(BUSINESS WIRE)–Strand Therapeutics, the programmable mRNA company developing breakthrough therapies for cancer and other diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of STX-001, a multi-mechanistic synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly into the tumor microenvironment.
“STX-001 has the potential to become the first programmable mRNA therapy in oncology,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics. “We’re thrilled to receive IND clearance to advance our program into patients, which represents an important milestone for our company. STX-001 represents a promising new approach for the treatment of solid tumors. We’re excited to continue evaluating our programmable mRNA technology across a number of therapeutic areas.”
STX-001 shows promise as a new approach to improve the efficacy of current immunotherapies for solid tumors. STX-001’s self-replicating mRNA technology induces immunogenic cancer cell death and promotes recruitment of T cells and NK cells to the tumor microenvironment, as well as their activation.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?